日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

VIKTORIA-1试验:Gedatolisib联合Fulvestrant,加或不加Palbociclib治疗激素受体阳性/HER2-/PIK3CA野生型晚期乳腺癌

Hurvitz, Sara A; Layman, Rachel M; Curigliano, Giuseppe; André, Fabrice; Cristofanilli, Massimo; Kim, Sung-Bae; Martínez Rodríguez, Jorge Luis; Nadal, Jorge C; Kim, Gun Min; Lo, Louisa; Remolina-Bonilla, Yuly A; Rosselli, Geronimo; Emile, George; Korbenfeld, Ernesto; Puig, Juan Manuel; Wesolowski, Robert; Martin, Miguel; Ring, Alistair; Han, Hyo S; Giordano, Antonio; Mutka, Sarah C; Moss, Keren; Suzuki, Sam; Sullivan, Brian; Gorbatchevsky, Igor; Pistilli, Barbara

Prognostic Significance of Pretreatment ¹⁸F-FDG PET/CT Parameters in Patients With ER+/HER2- Metastatic Breast Cancer Treated With CDK4/6 Inhibitors Plus Endocrine Therapy

CDK4/6抑制剂联合内分泌治疗治疗ER+/HER2-转移性乳腺癌患者中,治疗前¹⁸F-FDG PET/CT参数的预后意义

Suh, Minseung; Ryu, Jeongryul; Song, Hojin; Jeong, Jae Ho; Han, Sangwon; Jeong, Hyehyun; Kim, Jeong Eun; Shin, Yeokyeong; Jeong, Byung-Kwan; Lee, Hee Jin; Gong, Gyungyub; Ahn, Jin-Hee; Jung, Kyung Hae; Kim, Sung-Bae; Moon, Dae Hyuk

Ten-Year Follow-up Clinical Outcomes and the Role of Adjuvant Chemotherapy in HER2-Positive Patients with Microinvasive Breast Cancer

HER2阳性微浸润性乳腺癌患者十年随访临床结果及辅助化疗的作用

Shin, Yeokyeong; Lee, Soo-Young; Jeong, Hyehyun; Ahn, Jin-Hee; Jung, Kyung Hae; Kim, Sung-Bae; Kim, Hee Jeong; Lee, Jong Won; Son, Byung Ho; Ko, BeomSeok; Kim, Ji Sun; Chung, Il Yong; Lee, Hee Jin; Gong, Gyungyub; Lee, Sae Byul; Jeong, Jae Ho

Analysis of Plasma Epstein-Barr Virus DNA and Clinical Outcomes to Pembrolizumab or Chemotherapy in Recurrent/Metastatic Nasopharyngeal Cancer in KEYNOTE-122

KEYNOTE-122研究中,对复发/转移性鼻咽癌患者血浆中Epstein-Barr病毒DNA的分析以及帕博利珠单抗或化疗的临床疗效

Chan, Anthony T C; Lee, Victor Ho Fun; Hong, Ruey-Long; Ahn, Myung-Ju; Chong, Wan Qin; Spreafico, Anna; Kim, Sung-Bae; Ho, Gwo Fuang; Caguioa, Priscilla B; Ngamphaiboon, Nuttapong; Swaby, Ramona F; Wei, Bo; Webber, Andrea L; Kang, John; Gumuscu, Burak; Yuan, Jianda; Siu, Lillian L

Engineering a membrane protein chaperone to ameliorate the proteotoxicity of mutant huntingtin

通过工程改造膜蛋白伴侣来减轻突变亨廷顿蛋白的蛋白毒性

Jeonghyun Oh # ,Christy Catherine # ,Eun Seon Kim # ,Kwang Wook Min # ,Hae Chan Jeong ,Hyojin Kim ,Mijin Kim ,Seung Hae Ahn ,Nataliia Lukianenko ,Min Gu Jo ,Hyeon Seok Bak ,Sungsu Lim ,Yun Kyung Kim ,Ho Min Kim ,Sung Bae Lee ,Hyunju Cho

Increasing awareness of and referral to support services in advanced breast cancer: a global expert review and call-to-action for 2025-2035 (Goal 7)

提高对晚期乳腺癌患者及其家属的认识和转诊支持服务:2025-2035 年全球专家审查和行动呼吁(目标 7)

Kiely, Belinda; Travado, Luzia; Smith, Andrea L; Timeus, Isabelle Aloi; Kim, Sung-Bae; Haidinger, Renate; N M Nanre, Nampak; Rugo, Hope; Attfield, Georgia; Lewis, Alexandra; Cardoso, Fatima

Ensuring access to multidisciplinary care in advanced breast cancer: a global expert review and call-to-action for 2025-2035 (Goal 4)

确保晚期乳腺癌患者获得多学科诊疗:2025-2035 年全球专家审查和行动呼吁(目标 4)

Paluch-Shimon, Shani; Biganzoli, Laura; Torode, Julie; Mason, Ginny; Kim, Sung-Bae; Chidebe, Runcie C W; van Klinken, Merel; Attfield, Georgia; Lewis, Alexandra; Cardoso, Fatima

Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study

高危早期三阴性乳腺癌患者新辅助帕博利珠单抗联合化疗疗效的分子决定因素:一项开放标签、多队列 1b 期 KEYNOTE-173 研究的探索性分析

Dent, Rebecca; Cortés, Javier; Park, Yeon Hee; Muñoz-Couselo, Eva; Kim, Sung-Bae; Sohn, Joohyuk; Im, Seock-Ah; Holgado, Esther; Foukakis, Theodoros; Kümmel, Sherko; Yearley, Jennifer; Wang, Anran; Nebozhyn, Michael; Huang, Lingkang; Cristescu, Razvan; Jelinic, Petar; Karantza, Vassiliki; Schmid, Peter

Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study

伊姆鲁司群(一种口服选择性雌激素受体降解剂)联合HER2靶向治疗,无论是否联合阿贝西利,用于治疗ER阳性、HER2阳性晚期乳腺癌:来自EMBER 1a/1b期研究的结果

Bhave, Manali; Jhaveri, Komal L; Kaufman, Peter A; Aftimos, Philippe; Lombard, Janine; Giridhar, Karthik V; Im, Seock-Ah; Ma, Cynthia X; Lee, Kuo-Ting; Kim, Sung-Bae; Sohn, Joohyuk; Li, Yujia; Yuen, Eunice; Estrem, Shawn T; Nguyen, Bastien; Makena, Monish Ram; Ismail-Khan, Roohi; Beeram, Muralidhar

BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2- Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis

BRCA1/2 和其他易感基因在接受内分泌治疗(含或不含帕博西尼)的高危激素受体阳性/人表皮生长因子受体 2 阴性乳腺癌患者中的作用:一项 PENELOPE-B 研究的二次分析

Hahnen, Eric; Hauke, Jan; Gelmon, Karen; Marmé, Frederik; Ernst, Corinna; Martin, Miguel; Untch, Michael; Bonnefoi, Hervé; Knudsen, Erik; Im, Seock-Ah; DeMichele, Angela; Van't Veer, Laura; Kim, Sung-Bae; Bear, Harry; McCarthy, Nicole; Rhiem, Kerstin; Turner, Nicholas; Witkiewicz, Agnieszka; Rojo, Federico; Filipits, Martin; Martin, Lesley-Ann; Fasching, Peter A; Schem, Christian; Becker, Kerstin; García-Sáenz, José A; Kelly, Catherine M; Reimer, Toralf; Toi, Masakazu; Rugo, Hope S; Denkert, Carsten; Gnant, Michael; Makris, Andreas; Liu, Yuan; Valota, Olga; Felder, Bärbel; Weber, Karsten; Nekljudova, Valentina; Loibl, Sibylle